Back to Search
Start Over
Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
- Source :
- Radiation Oncology (London, England), Radiation Oncology, Vol 16, Iss 1, Pp 1-7 (2021)
- Publication Year :
- 2020
-
Abstract
- BackgroundThis retrospective study was to assess and compare the toxicity and efficacy of concurrent chemoradiotherapy (CCRT) with S-1 or docetaxel and cisplatin in patients with locally advanced esophageal squamous cell carcinoma (ESCC).MethodsPatients with locally advanced ESCC who received CCRT with S-1 (70 mg/m2twice daily on days 1–14, every 3 weeks for 2 cycles, S-1 group) or docetaxel (25 mg/m2) and cisplatin (25 mg/m2) on day 1 weekly (DP group) between 2014 and 2016 were retrospectively analyzed. Radiotherapy was delivered in 1.8–2.0 Gy per fraction to a total dose of 50–60 Gy. Treatment-related toxicities (Common Terminology Criteria for Adverse Events version 4.0), response rate, and survival outcomes were compared between groups.ResultsA total of 175 patients were included in this study (72 in the S-1 group and 103 in the DP group). Baseline characteristics were well balanced between the two groups. The incidence of grade 3–4 adverse events were significantly lower in the S-1 group than that of the DP group (22.2% vs. 45.6%,p = 0.002). In the DP group, elderly patients (> 60 years) had a significantly higher rate of grade 3–4 adverse events than younger patients (58.1% vs. 31.3%,p = 0.01). The objective overall response rate (complete response + partial response) was 68.1% in the S-1 group, and 73.8% the DP group (p = 0.497). The 3-year overall survival was 34.7% in the S-1 group, and 38.8% in the DP group (p = 0.422). The 3-year progression free survival in the DP group was higher than that in the S-1 group but without significant difference (33.0% vs. 25.0%,p = 0.275).ConclusionCCRT with S-1 is not inferior to CCRT with docetaxel and cisplatin and is better tolerated in in elderly patients with locally advanced ESCC.
- Subjects :
- Male
medicine.medical_specialty
Drug-Related Side Effects and Adverse Reactions
Esophageal Neoplasms
Esophageal cancer
R895-920
Docetaxel
Gastroenterology
03 medical and health sciences
Medical physics. Medical radiology. Nuclear medicine
0302 clinical medicine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Radiology, Nuclear Medicine and imaging
Progression-free survival
Adverse effect
RC254-282
030304 developmental biology
Aged
Retrospective Studies
Tegafur
Cisplatin
0303 health sciences
business.industry
Research
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Retrospective cohort study
Common Terminology Criteria for Adverse Events
Chemoradiotherapy
S-1
Middle Aged
medicine.disease
Survival Rate
Drug Combinations
Oxonic Acid
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
Female
Dose Fractionation, Radiation
Esophageal Squamous Cell Carcinoma
business
medicine.drug
Subjects
Details
- ISSN :
- 1748717X
- Volume :
- 16
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Radiation oncology (London, England)
- Accession number :
- edsair.doi.dedup.....51c29f483c100d501390e95e625438c1